Leap Therapeutics

Lyndra Therapeutics, Inc., based in Watertown, MA, is pioneering long-acting oral therapies aimed at transforming the patient experience by reducing the burden of daily medication regimens. Their innovative LYNX drug delivery platform has the potential for broad applicability across multiple therapeutic areas, including both approved and developing drugs. Generated from the website

AVI BioPharma is a biopharmaceutical company that develops drugs to treat life-threatening diseases using its patented third generation antisense technology. It has completed clinical trials with its NeuGene antisense drugs in more than 300 subjects, addressing cardiovascular restenosis, infectious diseases, cancer, polycystic kidney disease and drug metabolism. Its most advanced cardiovascular program is for restenosis, where it has completed Phase II trials, evaluating its drug, Resten-NG. AVI BioPharma is also in a Phase II clinical trial with a drug for Hepatitis C infection and its influenza A drug candidate has been confirmed to have efficacy against avian influenza H5N1 in preclinical studies. AVI BioPharma maintains a location in Portland, Ore.